人类遗传学优先筛选凝血级联蛋白靶点用于缺血性卒中预防
研究利用deCODE和UK Biobank的凝血蛋白遗传代理及VTE风险数据,对GIGASTROKE联盟的缺血性卒中及其亚型进行两样本孟德尔随机化和共定位分析。结果支持5种蛋白与缺血性卒中的因果关联,且均与心源性卒中亚型相关,其中γ'纤维蛋白原和凝血酶原还与大动脉粥样硬化性卒中相关。
要点
- 遗传代理的凝血因子XI、高分子量激肽原、凝血酶原、可溶性PROCR和γ'纤维蛋白原与心源性卒中相关。
- γ'纤维蛋白原和凝血酶原还与大动脉粥样硬化性卒中相关,无蛋白与小血管卒中相关。
- 蛋白C、蛋白S及因子V、VII的遗传代理与静脉血栓栓塞选择性相关。
核心结论
- 数据突出特定凝血级联成分与缺血性卒中发病相关,并识别出在VTE中作用不同的蛋白。
研究设计与样本
- 研究在deCODE(n=35 559)和UK Biobank(n=46 218)的循环蛋白水平全基因组关联研究及VTE风险(81 190例病例和1 419 671例对照)中识别并验证凝血级联蛋白的遗传代理。
- 研究对象均为欧洲血统。
- 采用两样本孟德尔随机化和共定位分析检验遗传代理与缺血性卒中(GIGASTROKE联盟62 100例病例和1 234 808例对照)及其亚型的关联。
主要发现
- 识别了30种凝血因子的遗传代理,跨性状关联再现了经典凝血生物学。
- 孟德尔随机化和共定位分析支持5种蛋白的遗传代理水平与缺血性卒中风险存在因果关联,且所有蛋白均与心源性卒中亚型相关:因子XI每增加1-SD的OR为1.31(95% CI 1.19-1.44;P=3.30×10-8)。
- 高分子量激肽原OR为1.19(95% CI 1.09-1.30;P=7.79×10-5),凝血酶原OR为1.83(95% CI 1.31-2.57;P=4.20×10-4),可溶性PROCR OR为0.88(95% CI 0.82-0.95;P=6.19×10-4)。
- γ'纤维蛋白原因水平降低导致VTE风险每倍增的OR为1.44(95% CI 1.25-1.66;P=3.96×10-7)。
- γ'纤维蛋白原和凝血酶原还与大动脉粥样硬化性卒中相关,无蛋白与小血管卒中风险相关;蛋白C、蛋白S及因子V和VII的遗传代理与VTE选择性相关。
临床怎么用
- 这些发现可能为新型抗凝药的开发提供信息,并优化其在卒中靶向人群中的使用。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While interindividual variations in concentration and function of coagulation cascade proteins are established risk factors for venous thromboembolism (VTE), their associations with arterial ischemic stroke are less well defined. METHODS: We identified and validated genetic proxies for lifelong, randomized perturbations of coagulation cascade proteins in genome-wide association studies of circulating protein levels (deCODE, n=35 559; UK Biobank, n=46 218) and of VTE risk (81 190 cases and 1 419 671 controls). Study participants were all of European ancestry. We performed 2-sample Mendelian randomization and colocalization analyses to test associations of these genetic proxies with risk of ischemic stroke (62 100 cases and 1 234 808 controls from the GIGASTROKE consortium) and ischemic stroke subtypes, and further contextualized associations with VTE and secondary efficacy and safety outcomes. RESULTS: We identified genetic proxies for 30 coagulation factors, with cross-trait associations recapitulating canonical coagulation biology. Mendelian randomization and colocalization analyses supported causal associations of genetically proxied levels of 5 proteins with risk of ischemic stroke, with all proteins associating with the cardioembolic stroke subtype: factor XI (odds ratio [OR] of cardioembolic stroke per 1-SD increase, 1.31 [95% CI, 1.19-1.44]; P=3.30×10-8), high-molecular-weight kininogen (OR, 1.19 [95% CI, 1.09-1.30]; P=7.79×10-5), prothrombin (OR, 1.83 [95% CI, 1.31-2.57]; P=4.20×10-4), soluble PROCR (protein C receptor; OR, 0.88 [95% CI, 0.82-0.95]; P=6.19×10-4), and γ' fibrinogen (OR per doubling in VTE risk due to lower γ' fibrinogen levels, 1.44 [95% CI, 1.25-1.66]; P=3.96×10-7). γ' Fibrinogen and prothrombin also associated with large artery atherosclerotic stroke, and no proteins were associated with small vessel stroke risk. By contrast, genetic proxies for several coagulation factors (including proteins C and S and factors V and VII) showed selective associations with VTE. CONCLUSIONS: These data highlight specific coagulation cascade components implicated in ischemic stroke pathogenesis, while identifying proteins with distinct roles in VTE. These findings may inform development of novel anticoagulants and optimize their use in targeted populations with stroke.
引用
- Daghlas I, Karhunen V, Kim AS, et al. Application of Human Genetics to Prioritize Coagulation Cascade Protein Targets for Ischemic Stroke Prevention. Stroke. 2025. PMID: 40188416. doi:10.1161/STROKEAHA.124.049808
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。